Dipòsit Digital de Documents de la UAB 4 registres trobats  La cerca s'ha fet en 0.01 segons. 
1.
12 p, 1.7 MB A Feasibility Study of Patients with Major Depression and Substance Use Disorders : Vortioxetine as Maintenance Treatment / Basurte-Villamor, Ignacio (Clínica López Ibor) ; Vega, Pablo (Madrid Salud) ; Roncero, Carlos (Universidad de Salamanca) ; Martínez-Raga, José (Hospital Universitari Doctor Peset (València)) ; Grau-López, Lara (Hospital Universitari Vall d'Hebron) ; Aguilar, Lourdes (Universidad de Salamanca) ; Torrens, Marta (Institut Hospital del Mar d'Investigacions Mèdiques) ; Szerman, Nestor (Hospital General Universitario Gregorio Marañón) ; Universitat Autònoma de Barcelona
Limited studies have evaluated the effectiveness of vortioxetine in real-world settings, and none of them has involved patients with dual depression (major depressive disorder [MDD] and substance use disorder [SUD]). [...]
2022 - 10.2147/NDT.S358782
Neuropsychiatric Disease and Treatment, Vol. 18 (may 2022) , p. 965-976  
2.
11 p, 963.4 KB Comparison of treatment outcomes in severe personality disorder patients with or without substance use disorders : a 36-month prospective pragmatic follow-up study / Lana, Fernando (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ; Sánchez-Gil, Carmen (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ; Adroher, Núria D. (Institut Hospital del Mar d'Investigacions Mèdiques) ; Pérez Solà, Víctor (Institut Hospital del Mar d'Investigacions Mèdiques) ; Feixas, Guillem (Universitat de Barcelona. Departament de Psiquiatria i de Psicobiologia Clínica) ; Martí-Bonany, Josep (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ; Torrens, Marta (Institut Hospital del Mar d'Investigacions Mèdiques)
Concurrent personality disorder (PD) and substance use disorder (SUD) are common in clinical practice. However, SUD is the main criterion for study exclusion in most psychotherapeutic studies of PD. [...]
2016 - 10.2147/NDT.S106270
Neuropsychiatric Disease and Treatment, Vol. 12 (june 2016) , p. 1477-1487  
3.
11 p, 334.9 KB Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder / Alvarez, Enric (Institut d'Investigació Biomèdica Sant Pau) ; Pérez Solà, Víctor (Centro de Investigación Biomédica en Red de Salud Mental) ; Artigas Pérez, Francesc (Institut d'Investigacions Biomèdiques de Barcelona) ; Universitat Autònoma de Barcelona
Vortioxetine is a new multimodal action antidepressant with two types of action: serotonin transporter (SERT) blockade and a strong affinity for several serotoninergic receptors. It is an antagonist of the 5-HT3 and 5-HT7 receptors, a partial agonist of 5-HT1B, and an agonist of 5-HT1A. [...]
2014 - 10.2147/NDT.S41387
Neuropsychiatric Disease and Treatment, Vol. 10 (july 2014) , p. 1297-1307  
4.
7 p, 211.7 KB Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection / Ascher-Svanum, Haya (Eli Lilly and Company, Indianapolis) ; Novick, Diego (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ; Haro Abad, Josep Maria (Institut de Recerca Sant Joan de Déu) ; Bertsch, Jordan (Institut de Recerca Sant Joan de Déu) ; McDonnell, David (Eli Lilly and Company, Indianapolis) ; Detke, Holland (Eli Lilly and Company, Indianapolis)
Little is known about the long-term changes in the functioning of schizophrenia patients receiving maintenance therapy with olanzapine long-acting injection (LAI), and whether observed changes differ from those seen with oral olanzapine. [...]
2014 - 10.2147/NDT.S61409
Neuropsychiatric Disease and Treatment, Vol. 10 (june 2014) , p. 1125-1131  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.